Une étude pour déterminer si le delgocitinib peut aider à réduire les symptômes chez les personnes atteintes de lichen scléreux (DELTA CARE 1)
Un essai de phase 3, en double aveugle, contrôlé par véhicule, pour étudier l'efficacité et la sécurité de la crème de delgocitinib deux fois par jour chez des participants adultes atteints de lichen scléreux pendant une période de traitement initiale de 12 semaines suivie d'une période de traitement de continuation de 40 semaines
The main objective of the study is to evaluate the efficacy of twice daily applications of delgocitinib cream compared with cream vehicle in the treatment of adult participants with mild to severe lichen sclerosus (LS). The researchers are focusing on female participants because LS is more likely to affect females compared to males.
The trial is conducted in 2 parts. Part 1 of the trial enrolls female participants with LS and results in the selection of the optimal dose for Part 2. The selected dose will then be evaluated in Part 2, which will enroll both female and male participants. Assessment of efficacy and safety of delgocitinib cream in male participants with LS will be evaluated in a substudy.
For each participant, the trial will last at least 55 weeks and up to 60 weeks.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- Phase 3
Contacts et emplacements
Coordonnées de l'étude
- Nom: Clinical Disclosure
- Numéro de téléphone: (+45) 4494 5888
- E-mail: disclosure@leo-pharma.com
Lieux d'étude
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3M 3Z4
- Recrutement
- LEO Pharma Investigational Site
-
-
New Brunswick
-
Fredericton, New Brunswick, Canada, E3B 1G9
- Recrutement
- LEO Pharma Investigational Site
-
-
Ontario
-
Guelph, Ontario, Canada, N1L 0B7
- Recrutement
- LEO Pharma Investigational Site
-
Newmarket, Ontario, Canada, L3Y 2R2
- Recrutement
- LEO Pharma Investigational Site
-
Richmond Hill, Ontario, Canada, L4E 4L6
- Recrutement
- LEO Pharma Investigational Site
-
Toronto, Ontario, Canada, M3B 0A7
- Recrutement
- LEO Pharma Investigational Site
-
Toronto, Ontario, Canada, M4W 2N4
- Recrutement
- LEO Pharma Investigational Site
-
Waterloo, Ontario, Canada, N2J 1C4
- Recrutement
- LEO Pharma Investigational Site
-
-
Quebec
-
Montreal, Quebec, Canada, H1Y 3L1
- Recrutement
- LEO Pharma Investigational Site
-
Québec, Quebec, Canada, G1W 4R4
- Recrutement
- LEO Pharma Investigational Site
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada, S7K 2C1
- Recrutement
- LEO Pharma Investigational Site
-
-
-
-
-
Liverpool, Royaume-Uni, L69 3BX
- Recrutement
- LEO Pharma Investigational Site
-
London, Royaume-Uni, SE1 9RT
- Recrutement
- LEO Pharma Investigational Site
-
-
-
-
Alabama
-
Birmingham, Alabama, États-Unis, 35244
- Recrutement
- LEO Pharma Investigational Site
-
-
Arizona
-
Phoenix, Arizona, États-Unis, 85006
- Recrutement
- LEO Pharma Investigational Site
-
Scottsdale, Arizona, États-Unis, 85259
- Recrutement
- LEO Pharma Investigational Site
-
-
California
-
Fremont, California, États-Unis, 94538
- Recrutement
- LEO Pharma Investigational Site
-
-
Connecticut
-
Middlebury, Connecticut, États-Unis, 06762
- Recrutement
- LEO Pharma Investigational Site
-
-
District of Columbia
-
Washington D.C., District of Columbia, États-Unis, 20037
- Recrutement
- LEO Pharma Investigational Site
-
-
Florida
-
Boca Raton, Florida, États-Unis, 33486
- Recrutement
- LEO Pharma Investigational Site
-
Clearwater, Florida, États-Unis, 33756
- Recrutement
- LEO Pharma Investigational Site
-
Jacksonville, Florida, États-Unis, 32224
- Recrutement
- LEO Pharma Investigational Site
-
Miami, Florida, États-Unis, 33186
- Recrutement
- LEO Pharma Investigational Site
-
Tampa, Florida, États-Unis, 33609
- Recrutement
- LEO Pharma Investigational Site
-
-
Michigan
-
Northville, Michigan, États-Unis, 48167
- Recrutement
- LEO Pharma Investigational Site
-
-
Minnesota
-
Rochester, Minnesota, États-Unis, 55905
- Recrutement
- LEO Pharma Investigational Site
-
-
New York
-
New York, New York, États-Unis, 10036
- Recrutement
- LEO Pharma Investigational Site
-
New York, New York, États-Unis, 10029
- Recrutement
- LEO Pharma Investigational Site
-
-
North Carolina
-
Chapel Hill, North Carolina, États-Unis, 27516
- Recrutement
- LEO Pharma Investigational Site
-
-
Ohio
-
Bexley, Ohio, États-Unis, 43209
- Recrutement
- LEO Pharma Investigational Site
-
-
Oregon
-
Portland, Oregon, États-Unis, 97239
- Recrutement
- LEO Pharma Investigational Site
-
-
Texas
-
Dallas, Texas, États-Unis, 75235
- Recrutement
- LEO Pharma Investigational Site
-
-
Utah
-
Murray, Utah, États-Unis, 84107
- Recrutement
- LEO Pharma Investigational Site
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria
-
Signed and dated informed consent has been obtained prior to any protocol-related procedures.
-
Age ≥18 years at the time of signing informed consent.
-
Participant is able to comply with clinic visits and trial requirements and procedures, as assessed by the investigator.
-
Female participants or male participants (assigned sex at birth and has not had any gender affirming medical procedures to their genital area) with LS in the anogenital area, regardless of treatment history. The diagnosis must be based on typical clinical features and supported by biopsy. A biopsy must be taken if there is no previous documented biopsy to support the diagnosis.
Note: Participants who also have LS-affected areas outside the anogenital area are allowed to be enrolled but these areas will not be treated with investigational medicinal product (IMP). Participants with newly diagnosed LS can be included, as well as participants who have progressive LS (including existing architectural changes).
-
Disease severity graded as mild to severe at screening and baseline according to IGA-LS score (ie, an IGA-LS score of ≥2).
-
Female participants: A woman of childbearing potential (WOCBP) must agree to use a highly effective or acceptable form of birth control throughout the trial up until the last application of IMP. Male participants: Contraceptive requirements are not applicable for male participants.
Exclusion Criteria
-
Participants with atypical presentation of LS in the anogenital area where the diagnosis is uncertain, or the suspicion of malignancy exists.
-
Female participants: History of vulvar squamous cell carcinoma (SCC), including precursor lesions (eg, human papillomavirus-independent [HPV-I] vulvar intraepithelial neoplasia [VIN] and high-grade squamous intraepithelial lesion). Male participants: History of penile SCC, including precursor lesions.
-
Female participants only: Participants with any abnormal cytology result at screening following a positive high-risk human papillomavirus (hrHPV) screening test.
-
Active dermatologic or gynecologic conditions that could confound the diagnosis of LS or interfere with assessment of the IMP (eg, urinary incontinence-associated dermatitis, genital lichen planus, and genital psoriasis), as assessed by the investigator.
-
Participants with severe urinary incontinence. Incontinence is considered severe if it occurs on most days and more than a few drops at a time.
-
Female participants: Suspected clinically (or confirmed diagnostically) of having active infection in the anogenital area, including candidiasis, Chlamydia trachomatis, Trichomonas vaginalis, Neisseria gonorrhoeae, Mycoplasma genitalium, bacterial vaginosis, or herpes simplex. Participants who test positive for sexually transmitted disease (STD)/bacterial vaginosis (BV)/anogenital candidiasis during screening can be treated, and if repeat testing is negative, these participants can be enrolled. If treatment is needed, the screening period can be extended to 6 weeks to accommodate the treatment and washout requirements.
Male participants: Suspected clinically (or confirmed diagnostically) of having active infection in the anogenital area, including candidiasis, Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, or herpes simplex. Participants who test positive for STD/anogenital candidiasis during screening can be treated, and if repeat testing is negative, these participants can be enrolled. If treatment is needed, the screening period can be extended to 6 weeks to accommodate the treatment and washout requirements.
-
Clinically significant infection within 4 weeks prior to baseline which, in the opinion of the investigator, may compromise the safety of the participant in the trial, interfere with evaluation of the IMP, or reduce the participant's ability to participate in the trial.
Clinically significant infections are defined as:
- A systemic infection.
- A serious skin infection requiring parenteral (intravenous or intramuscular) antibiotics, antiviral, or antifungal medication.
-
History of any known primary immunodeficiency disorder including a positive human immunodeficiency virus test at screening, or the participant taking antiretroviral medications as determined by medical history and/or participant's verbal report.
-
Major surgery within 8 weeks prior to screening or planned in-patient surgery or hospitalization during the trial period.
-
History of cancer:
• Female participants: Participants who have had basal cell carcinoma or localized SCC of the skin (outside the anogenital area), or in situ carcinoma of the cervix are eligible provided that curative therapy was successfully completed at least 12 months prior to screening.
Participants who have had other malignancies (except vulvar SCC) are eligible provided that the participant is in remission and curative therapy was completed at least 5 years prior to screening.
• Male participants: Participants who have had basal cell carcinoma or localized SCC of the skin (outside the anogenital area) are eligible provided that curative therapy was successfully completed at least 12 months prior to screening.
Participants who have had other malignancies (except penile SCC) are eligible provided that the participant is in remission and curative therapy was completed at least 5 years prior to screening.
-
Positive hepatitis B surface antigen and/or hepatitis B core antibody and positive for hepatitis B virus deoxyribonucleic acid (participants who have tested positive for hepatitis B core antibody are eligible if tests for hepatitis B surface antigen and hepatitis B virus deoxyribonucleic acid are negative), or positive hepatitis C virus antibody serology confirmed by hepatitis C virus ribonucleic acid (RNA) at screening.
-
Known or suspected hypersensitivity to any component(s) of the IMP(s).
-
Any disorder which is not stable and according to the investigator could:
- Affect the safety of the participant throughout the trial.
- Hinder the participant's ability to complete the trial.
Examples include, but are not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, immunological, and psychiatric disorders, and major physical impairment.
-
Any abnormal finding which according to the investigator may:
- Put the participant at risk because of their participation in the trial.
- Influence the participant's ability to complete the trial.
The abnormal finding must be clinically significant and observed during the screening period. Examples include abnormal findings in physical examination, vital signs, electrocardiogram (ECG), hematology, or biochemistry.
-
Current or recent chronic alcohol or drug abuse, or any other condition associated with poor compliance as judged by the investigator.
-
Female participants only: Women who are pregnant or lactating. For women of childbearing potential, a negative pregnancy test is required at screening.
-
Systemic treatment with immunosuppressive drugs (eg, methotrexate, cyclosporine), immunomodulating drugs, retinoids, or corticosteroids within 4 weeks prior to baseline.
-
Cutaneously applied treatment with immunomodulators (eg, topical calcineurin inhibitor [TCI]) or topical corticosteroid (TCS) on the anogenital area within 2 weeks before baseline.
-
Use of systemic or topical Janus kinase (JAK) inhibitors (including delgocitinib) within 4 weeks before baseline.
-
Systemic or cutaneous (applied in the anogenital area) use of antibiotics, antiparasitics, antivirals, or antifungals within 1 week before baseline.
-
Treatment with any marketed biological therapy or investigational biologic agents:
- Any cell-depleting agent including but not limited to rituximab: within 6 months prior to baseline, or until the lymphocyte count returns to normal, whichever is longer.
- Other biologics: within 3 months or 5 half-lives, whichever is longer, prior to baseline.
-
Treatment with any non-marketed drug substance (that is, an agent that has not yet been made available for clinical use following registration) within 4 weeks prior to baseline or 5 half-lives, whichever is longer.
-
Light-based therapy on the anogenital area and treatments with platelet-rich plasma within 4 weeks prior to baseline.
-
Cutaneous treatments applied within 1 week before baseline in regions other than the anogenital area which could interfere with clinical trial evaluations or pose a safety concern.
-
Other cutaneous therapies or therapeutic procedures on the anogenital area within 1 week before baseline.
-
Surgical treatment for anogenital LS in the past 6 months or have not recovered fully from an earlier surgical procedure in the anogenital area.
-
Female participants only: Participants who are receiving doses that are not stable for topical estrogens (<4 weeks before screening), and hormonal contraceptives and hormone replacement therapy (HRT) medications (<3 months before screening).
-
Current participation in any other interventional clinical trial.
-
Previously randomized in this clinical trial.
-
Previously randomized in a clinical trial with delgocitinib.
-
Clinically important laboratory abnormalities:
- Participants with alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) values ≥2×the upper limit of normal (ULN) with total bilirubin (BIL) ≥1.5×ULN (unless elevated BIL is related to Gilbert Meulengracht Syndrome).
- Participants with ALT and/or AST values ≥3×ULN.
- Participants with severe renal impairment (estimated glomerular filtration rate [eGFR]<30 mL/min/1.73 m2).
-
Employees of the trial site, or any other individuals directly involved with the planning or conduct of the trial, or immediate family members of such individuals.
-
Participants who are legally institutionalized.
-
Only applicable in France: Participant not affiliated with or not a beneficiary of a social security scheme.
-
Male participants only: Participants who currently need or are expected during the entire study period to require any type of surgical treatment for LS (eg, circumcision, urethroplasty, adhesiolysis) or tool-assisted local treatment (eg, catheter, cotton swabs, applicators, dilators, etc.) for LS involving the urethra. Application of study treatment of the urethral meatus is allowed if it can be applied by the participant's hand or fingers only.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Part 1: Delgocitinib Cream 20 mg/g
Participants will receive delgocitinib cream 20 mg/g twice daily (BID) in both the 12-week initial treatment period and the 40-week continuation treatment period. |
Participants will receive delgocitinib BID via topical application. |
|
Expérimental: Part 1: Delgocitinib Cream 20 mg/g, then Cream Vehicle
Participants will receive delgocitinib cream 20 mg/g BID in the 12-week initial treatment period, then cream vehicle BID in the 40-week continuation treatment period. |
Participants will receive delgocitinib BID via topical application. Participants will receive cream vehicle BID via topical administration. |
|
Expérimental: Part 1: Delgocitinib Cream 8 mg/g
Participants will receive delgocitinib cream 8 mg/g BID in both the 12-week initial treatment period and the 40-week continuation treatment period. |
Participants will receive delgocitinib BID via topical application. |
|
Expérimental: Part 1: Delgocitinib Cream 8 mg/g, then Cream Vehicle
Participants will receive delgocitinib cream 8 mg/g BID in the 12-week initial treatment period, then cream vehicle BID in the 40-week continuation treatment period. |
Participants will receive delgocitinib BID via topical application. Participants will receive cream vehicle BID via topical administration. |
|
Expérimental: Part 1: Cream Vehicle, then Delgocitinib Cream 20 mg/g
Participants will receive cream vehicle BID in the 12-week initial treatment period, then delgocitinib cream 20 mg/g BID in the 40-week continuation treatment period. |
Participants will receive delgocitinib BID via topical application. Participants will receive cream vehicle BID via topical administration. |
|
Expérimental: Part 1: Cream Vehicle, then Delgocitinib Cream 8 mg/g
Participants will receive cream vehicle BID in the 12-week initial treatment period, then delgocitinib cream 8 mg/g BID in the 40-week continuation treatment period. |
Participants will receive delgocitinib BID via topical application. Participants will receive cream vehicle BID via topical administration. |
|
Comparateur placebo: Part 1: Cream Vehicle
Participants will receive cream vehicle BID in both the 12-week initial treatment period and the 40-week continuation treatment period. |
Participants will receive cream vehicle BID via topical administration. |
|
Expérimental: Part 2: Delgocitinib Cream (Selected Dose)
Participants will receive delgocitinib cream, at the selected dose from Part 1, BID in both the 12-week initial treatment period and the 40-week continuation treatment period. |
Participants will receive delgocitinib BID via topical application. |
|
Expérimental: Part 2: Delgocitinib Cream (Selected Dose), then Cream Vehicle
Participants will receive delgocitinib cream, at the selected dose from Part 1, BID in the 12-week initial treatment period, then cream vehicle BID in the 40-week continuation treatment period. |
Participants will receive delgocitinib BID via topical application. Participants will receive cream vehicle BID via topical administration. |
|
Expérimental: Part 2: Cream Vehicle, then Delgocitinib Cream (Selected Dose)
Participants will receive cream vehicle BID in the 12-week initial treatment period, then delgocitinib cream, at the selected dose from Part 1, BID in the 40-week continuation treatment period. |
Participants will receive delgocitinib BID via topical application. Participants will receive cream vehicle BID via topical administration. |
|
Comparateur placebo: Part 2: Cream Vehicle
Participants will receive cream vehicle BID in both the 12-week initial treatment period and the 40-week continuation treatment period. |
Participants will receive cream vehicle BID via topical administration. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Nombre de participants atteignant IGA-LS TS à la semaine 12
Délai: Semaine 12
|
Semaine 12
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
Nombre de participants atteignant IGA-LS TS à la semaine 8
Délai: Semaine 8
|
Semaine 8
|
|
Évolution du score clinique de lichen scléreux (CLISSCO) entre la valeur initiale et la semaine 12
Délai: Baseline à la Semaine 12
|
Baseline à la Semaine 12
|
|
Nombre de participants atteignant une réduction du score de l'échelle numérique d'évaluation de la douleur cutanée (NRS) (moyenne hebdomadaire) de ≥4 points par rapport à la valeur initiale à la semaine 12 chez les participants avec un score de douleur cutanée NRS initial ≥4
Délai: De la ligne de base à la semaine 12
|
De la ligne de base à la semaine 12
|
|
Nombre de participants atteignant une réduction du score NRS de douleur cutanée (moyenne hebdomadaire) de ≥4 points par rapport à la valeur initiale à la semaine 8 chez les participants avec un score NRS de douleur cutanée initial ≥4
Délai: Baseline à la semaine 8
|
Baseline à la semaine 8
|
|
Nombre de participants atteignant une réduction du score NRS de prurit (moyenne hebdomadaire) de ≥ 4 points par rapport à la valeur de base à la semaine 12 chez les participants avec un score NRS de prurit de base ≥ 4
Délai: De la ligne de base à la semaine 12
|
De la ligne de base à la semaine 12
|
|
Nombre de participants atteignant une réduction du score NRS du prurit (moyenne hebdomadaire) de ≥4 points par rapport à la valeur initiale jusqu'à la semaine 8 chez les participants ayant un score NRS du prurit initial ≥4
Délai: De la ligne de base à la semaine 8
|
De la ligne de base à la semaine 8
|
|
Variation du score de l'Indice de Qualité de Vie Vulvaire (VQLI) entre le début de l'étude et la semaine 12
Délai: De la ligne de base à la semaine 12
|
De la ligne de base à la semaine 12
|
|
Nombre de participants ayant atteint l'IGA-LS TS à la semaine 52
Délai: Semaine 52
|
Semaine 52
|
|
Changement du score CLISSCO entre la valeur initiale et la semaine 52
Délai: De la ligne de base à la semaine 52
|
De la ligne de base à la semaine 52
|
|
Nombre de participants ayant atteint l'IGA-LS TS à la semaine 52 parmi les participants ayant atteint l'IGA-LS TS à la semaine 12
Délai: Semaine 52
|
Semaine 52
|
|
Nombre de participants ayant atteint un score IGA-LS de 0 ou 1 à la semaine 52 parmi les participants ayant atteint la TS IGA-LS à la semaine 12
Délai: Semaine 52
|
Semaine 52
|
|
Temps jusqu'à IGA-LS TS de la ligne de base à la semaine 52
Délai: De la base au 52e semaine
|
De la base au 52e semaine
|
|
Délai jusqu'à IGA-LS ≥2 de la semaine 12 à la semaine 52 chez les participants ayant atteint IGA-LS TS à la semaine 12
Délai: Semaine 12 à Semaine 52
|
Semaine 12 à Semaine 52
|
|
Nombre de participants n'ayant pas présenté d'augmentation du score du domaine des modifications architecturales CLISSCO entre la valeur initiale et la semaine 52
Délai: Baseline à la semaine 52
|
Baseline à la semaine 52
|
|
Nombre de participants présentant une réduction du score NRS de la douleur cutanée (moyenne hebdomadaire) de ≥4 points entre le début de l'étude et la semaine 52 chez les participants ayant un score NRS de la douleur cutanée de départ ≥4
Délai: De la ligne de base à la semaine 52
|
De la ligne de base à la semaine 52
|
|
Nombre de participants ayant obtenu une réduction du score NRS de prurit (moyenne hebdomadaire) de ≥4 points par rapport à la valeur de base jusqu'à la semaine 52 chez les participants avec un score NRS de prurit de base ≥4
Délai: De la ligne de base à la semaine 52
|
De la ligne de base à la semaine 52
|
|
Nombre d'événements indésirables émergents du traitement (TEAEs) de la ligne de base à la semaine 12
Délai: De la ligne de base à la semaine 12
|
De la ligne de base à la semaine 12
|
|
Nombre d'effets indésirables survenus sous traitement de la semaine 12 à la semaine 54
Délai: De la semaine 12 à la semaine 54
|
De la semaine 12 à la semaine 54
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Medical Expert, LEO Pharma
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- LP0133-2395
- 2025-524873-17-00 (Ctis)
- U1111-1333-1675 (Autre identifiant: World Health Organization (WHO))
- 2025 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .